DEFINE AND DEVELOPMENT OF SMART DRUG TROUGH QUALITY BY DESIGN

Venkateswarlu Kothagorla

Kothagorla. Venkateswarlu Priyadarshini Institute of Pharmaceutical Education and Research, 5th Mile, Pulladigunta, Guntur-522017, Andhra Pradesh, India.

Abstract

The newest approach in pharmaceutical production linked to quality is called Quality by Design to guarantee that premium-grade pharmaceuticals are produced, Pharmaceutical Quality by Design, or is discussed in this article. A description of Quality by Design is provided along with a list of its constituent parts. Every unit activity has its own set of quality metrics. The use of Quality by Design and its associated measures can yield significant benefits for pharmaceutical goods. The foundation of pharmaceutical R&D is high-quality drugs and the procedures used in their production. A product's quality cannot be easily verified because this paper just summarises the product's quality profile and the most important components of Quality by Design. Quality by design and end-product testing are two ways to compare the quality of various goods. Quality by Design is based on the ICH Guidelines. ICH guidelines apply to the development of medications and the application of quality control methods. The research and manufacturing of pharmaceuticals might profit from Quality by Design As the product develops and is designed, it is crucial to determine the desired product performance report under these ideas. The TPP, QTPP, and CQA stand for target product profile.

Keywords: Quality by design target Product Profile (TPP), Target Product Quality Profile (TPQP), Quality risk management (QRM), Critical material attributes (CMA), Critical process parameters (CPP), control strategy

Downloads

Download data is not yet available.

References

1. Nadpara NP, Thumar RV, Kalola VN, Patel PB. Quality by design (QbD): a complete review. Int J Pharm Sci Rev Res. 2012;17(2):20-28.
2. Woodcock J. The concept of pharmaceutical quality. Am Pharm Rev. 2004;7(6):10-15.
3. Singh J. International conference on harmonization of technical requirements for registration of pharmaceuticals for human use. J Pharmacol Pharmacother. 2015;6(3):185-187.
4. Nkuku SJ, Kumar D, Rishikanta L. Review article on quality by design in pharmaceutics: enhancing drug development and manufacturing. Pharmaceutics. 2024.
5. Singh J. International conference on harmonization of technical requirements for registration of pharmaceuticals for human use. J Pharmacol Pharmacother. 2015;6(3):185-187.
6. Drakulich A. Critical challenges to implementing QbD: a Q&A with FDA. Pharm Technol. 2009;33(10):90-94.
7. Vogt FG, Kord AS. Development of quality-by-design analytical methods. J Pharm Sci. 2011;100(3):797-812.
8. Darkunde SL. A review on quality by design. Int J Pharm Chem Anal. 2018;5(1):1-6.
9. Shah RB, Khan MA. The science and regulatory perspectives of emerging controlled release dosage forms. In: Oral Controlled Release Formulation Design and Drug Delivery: Theory to Practice. Hoboken (NJ): John Wiley & Sons; 2010. p. 337-349.
10. US Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: modified release solid oral dosage forms scale-up and postapproval changes (SUPAC-MR): chemistry, manufacturing and controls, in vitro dissolution testing, and in vivo bioequivalence documentation. Rockville (MD): FDA; 1997.
11. Ramalingam P, Ganapaty S, Rao CB, Reddy DR. Quantitative structural activity relationship (QSAR) study of some synthesized quinoxaline derivatives as growth inhibitor against Mycobacterium tuberculosis H37Rv. Inventi Rapid Med Chem. 2012.
12. Chandu BR, Nama S, Kanala K, Challa BR, Shaik RP, Khagga M. Quantitative estimation of riluzole in human plasma by LC-ESI-MS/MS and its application to a bioequivalence study. Anal Bioanal Chem. 2010;398(3):1367-1374.
13. Awen BZ, Katakam P, Rao CB, Mohammed SA, Alokbe TO. Design and in vitro evaluation of controlled release cephalexin subgingival films using natural biodegradable polymer. Recent Res Sci Technol. 2010;2(4):1-7.
14. Awen BZ, Hwisa NT, Katakam P, Chandu BR, Kotaiah S, Kumari S. Development and validation of novel spectrophotometric methods for the determination of metronidazole and ofloxacin alone and their combination in pH 6.8 phosphate buffer. Inventi Rapid Pharm Anal Qual Assur. 2010;24(7):28-35.
15. Ramalingam P, Ganapaty S, Rao CB. Quantitative structure activity relationship (3D-QSAR) studies of some quinoxaline derivatives as growth inhibitor against Mycobacterium tuberculosis H37Rv. Indian J Pharm Sci. 2009;71(2):207-208.
16. Katakam P, Padala NR, Chandu BR, Elfituri A, Kumari S, Kommu R. Design of lamivudine XR matrix tablets: influence of HPMC and PEO on in vitro drug release and bioavailability in rabbits. J Pharm Res. 2013;6(8):845-852.